Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy.
Adult
Age Factors
Aged
Aged, 80 and over
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Clinical Decision-Making
Disease Progression
Feasibility Studies
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Neoplasm Recurrence, Local
Pancreatectomy
/ adverse effects
Pancreatic Neoplasms
/ diagnosis
Progression-Free Survival
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
15
12
2021
Statut:
ppublish
Résumé
In this study, we retrospectively assessed the feasibility and prognostic efficacy of perioperative chemo(radio)therapy for pancreatic cancer (PC) patients according to age. A total of 556 consecutive patients who underwent curative-intent pancreatectomy for PC between 2000 and 2018 were enrolled. Of the 556 patients who underwent resection, 95 (17%) were elderly (age, ≥75 years). Postoperative complications did not significantly differ between the 2 age groups, and postoperative prognoses were also similar (recurrence-free survival [RFS], P = 0.68; overall survival [OS], P = 0.28). In this cohort, 103 patients (19%) underwent preoperative chemo(radio)therapy, and 417 (77%) underwent postoperative chemotherapy. Perioperative therapy was found to be significantly beneficial for younger patients (preoperative therapy: RFS, P = 0.006; OS, P < 0.001; postoperative therapy: RFS, P < 0.001; OS, P < 0.001). Conversely, no significant survival benefit of perioperative therapy was found for the elderly (preoperative therapy: RFS, P = 0.28; OS, P = 0.44; postoperative therapy: RFS, P = 0.77; OS, P = 0.08). This study demonstrated that, although perioperative therapy is feasible for selected elderly patients with PC, this approach might not be as beneficial as it is for younger PC patients.
Identifiants
pubmed: 33370021
doi: 10.1097/MPA.0000000000001712
pii: 00006676-202101000-00006
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-46Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res . 2014;74:2913–2921.
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg . 2015;261:12–17.
Okada KI, Shimokawa T, Hirono S, et al. Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer: a prospective multicenter phase II trial (NAC-GA Trial). Oncology . 2017;93:343–346.
Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg . 2019;270:400–413.
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol . 2013;31:23–29.
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol . 2017;35:515–522.
Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet . 2009;374:1196–1208.
Kanda M, Koike M, Tanaka C, et al. Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surg . 2019;19:143.
Kanda M, Fujii T, Suenaga M, et al. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Pancreas . 2014;43:951–958.
Kinoshita S, Sho M, Yanagimoto H, et al. Potential role of surgical resection for pancreatic cancer in the very elderly. Pancreatology . 2015;15:240–246.
Nakao A, Takeda S, Inoue S, et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg . 2006;30:976–982; discussion 983-984.
Nakao A. The mesenteric approach in pancreatoduodenectomy. Dig Surg . 2016;33:308–313.
Masuda T, Dann AM, Elliott IA, et al. A comprehensive assessment of accurate lymph node staging and preoperative detection in resected pancreatic cancer. J Gastrointest Surg . 2018;22:295–302.
Tseng DS, van Santvoort HC, Fegrachi S, et al. Diagnostic accuracy of CT in assessing extra-regional lymphadenopathy in pancreatic and peri-ampullary cancer: a systematic review and meta-analysis. Surg Oncol . 2014;23:229–235.
Tsuchida H, Fujii T, Mizuma M, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery . 2019;166:997–1003.
NCCN Clinical practice guidelines in oncology (NCCN guidelines). Version 3.2017. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx . Accessed April 1, 2019.
Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours . 7th ed. Oxford, United Kingdom: Wiley-Blackwell; 2011.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg . 2009;250:187–196.
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery . 2017;161:584–591.
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet . 2016;388:248–257.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA . 2013;310:1473–1481.
Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg . 2008;195:757–762.
Takeda S, Inoue S, Kaneko T, et al. The role of adjuvant therapy for pancreatic cancer. Hepatogastroenterology . 2001;48:953–956.
Nakayama S, Takeda S, Kawase Y, et al. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg . 2004;240:840–844.
Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci . 2013;20:590–600.
Yamada S, Takami H, Sonohara F, et al. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. J Hepatobiliary Pancreat Sci . 2019;26:235–241.
Fujii T, Yamada S, Murotani K, et al. Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Medicine (Baltimore) . 2015;94:e1647.
Fujii T, Satoi S, Yamada S, et al. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. J Gastroenterol . 2017;52:81–93.
Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med . 2011;364:1817–1825.
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol . 2013;20:3794–3801.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med . 2013;369:1691–1703.
Murakami Y, Uemura K, Sudo T, et al. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol . 2017;79:801–811.
Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) . 2014;16:430–438.
Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas . 2012;41:985–992.
Gebhardt C, Meyer W, Reichel M, et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg . 2000;385:14–20.
Hirai I, Kimura W, Ozawa K, et al. Perineural invasion in pancreatic cancer. Pancreas . 2002;24:15–25.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med . 2014;371:2140–2141.
Raufi AG, Manji GA, Chabot JA, et al. Neoadjuvant treatment for pancreatic cancer. Semin Oncol . 2019;46:19–27.
Kimura Y, Nakamura T, Hayashi T, et al. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). Ann Gastroenterol Surg . 2019;3:523–533.
Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg . 2019 Apr 2. [Epub ahead of print].
Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg . 2018;268:215–222.
Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol . 2004;22:4626–4631.
Frakes JM, Strom T, Springett GM, et al. Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol . 2015;6:127–132.
Morizane C, Okusaka T, Ito Y, et al. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients. Oncology . 2005;68:432–437.
Miura JT, Krepline AN, George B, et al. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery . 2015;158:1545–1555.